{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:01:16Z","timestamp":1762783276019,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hanmi Pharmaceutical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40261-025-01482-3","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:02:10Z","timestamp":1758009730000},"page":"803-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and Safety of Very-Low-Dose Rosuvastatin\u2013Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study"],"prefix":"10.1007","volume":"45","author":[{"given":"Ji Woong","family":"Roh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon-hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-won","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-4645","authenticated-orcid":false,"given":"SungA","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the HM-ROS-OS-2102 Study Investigator Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"1482_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2471\/blt.10.079947","volume":"89","author":"GA Roth","year":"2011","unstructured":"Roth GA, Fihn SD, Mokdad AH, Aekplakorn W, Hasegawa T, et al. High total serum cholesterol, medication coverage and therapeutic control: an analysis of National Health Examination Survey data from eight countries. Bull World Health Organ. 2011;89:92\u2013101. https:\/\/doi.org\/10.2471\/blt.10.079947.","journal-title":"Bull World Health Organ"},{"key":"1482_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.thromres.2019.09.034","volume":"183","author":"J Sundb\u00f8ll","year":"2019","unstructured":"Sundb\u00f8ll J, Larsen AP, Veres K, Adelborg K, S\u00f8rensen HT. Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: a population-based cohort study. Thromb Res. 2019;183:124\u201330. https:\/\/doi.org\/10.1016\/j.thromres.2019.09.034.","journal-title":"Thromb Res"},{"key":"1482_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"1482_CR4","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","volume":"291","author":"DI Chasman","year":"2004","unstructured":"Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291:2821\u20137. https:\/\/doi.org\/10.1001\/jama.291.23.2821.","journal-title":"JAMA"},{"key":"1482_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","volume":"67","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, Taylo B. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395\u2013410. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.071.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1482_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","volume":"120","author":"DD Waters","year":"2009","unstructured":"Waters DD, Brotons C, Chiang CW, Ferri\u00e8res J, Foody J, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.838466.","journal-title":"Circulation"},{"key":"1482_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"\u017d Reiner","year":"2019","unstructured":"Reiner \u017d, De Backer G, Fras Z, Kotseva K, Tokg\u00f6zo\u011flu L, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2014findings from the EUROASPIRE V survey. Atherosclerosis. 2019;285:135\u201346. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.03.014.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1482_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3803\/EnM.2011.26.4.297","volume":"26","author":"HS Kim","year":"2011","unstructured":"Kim HS, Yu SH, Oh J, Lee CJ, Kang SM, et al. Attainment rate of low-density lipoprotein cholesterol goal and related factors in Korean patients with atherosclerotic cardiovascular disease. Endocrinol Metab (Seoul). 2011;26(4):297\u2013303. https:\/\/doi.org\/10.3803\/EnM.2011.26.4.297.","journal-title":"Endocrinol Metab (Seoul)."},{"issue":"3","key":"1482_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","volume":"99","author":"JK Liao","year":"2007","unstructured":"Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99(3):410\u20134. https:\/\/doi.org\/10.1016\/j.amjcard.2006.08.051.","journal-title":"Am J Cardiol"},{"key":"1482_CR10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1592\/phco.23.14.1463.31942","volume":"23","author":"EA Nutescu","year":"2003","unstructured":"Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy. 2003;23:1463\u201374. https:\/\/doi.org\/10.1592\/phco.23.14.1463.31942.","journal-title":"Pharmacotherapy"},{"key":"1482_CR11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/nejmoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/nejmoa1410489.","journal-title":"N Engl J Med"},{"key":"1482_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd012502.pub2","volume":"11","author":"S Zhan","year":"2018","unstructured":"Zhan S, Tang M, Liu F, Xia P, Shu M, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11:CD012502. https:\/\/doi.org\/10.1002\/14651858.cd012502.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1482_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/s0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400:380\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(22)00916-3.","journal-title":"Lancet"},{"key":"1482_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.bjp.0704260","volume":"134","author":"M van Heek","year":"2001","unstructured":"van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001;134:409\u201317. https:\/\/doi.org\/10.1038\/sj.bjp.0704260.","journal-title":"Br J Pharmacol"},{"key":"1482_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/17512433.2021.1925539","volume":"14","author":"V Barrios","year":"2021","unstructured":"Barrios V, Escobar C. Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. Expert Rev Clin Pharmacol. 2021;14:793\u2013806. https:\/\/doi.org\/10.1080\/17512433.2021.1925539.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1482_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jama.2023.2487","volume":"329","author":"SJ Hong","year":"2023","unstructured":"Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023;329:1078\u201387. https:\/\/doi.org\/10.1001\/jama.2023.2487.","journal-title":"JAMA"},{"key":"1482_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","volume":"29","author":"SO Almeida","year":"2019","unstructured":"Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med. 2019;29:451\u20135. https:\/\/doi.org\/10.1016\/j.tcm.2019.01.001.","journal-title":"Trends Cardiovasc Med"},{"key":"1482_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/circresaha.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229\u201343. https:\/\/doi.org\/10.1161\/circresaha.116.308537.","journal-title":"Circ Res"},{"key":"1482_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075837","volume":"383","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, Hong SJ, Kang WC, Hong BK, Lee JY, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023;383:e075837. https:\/\/doi.org\/10.1136\/bmj-2023-075837.","journal-title":"BMJ"},{"key":"1482_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3904\/kjim.2018.312","volume":"35","author":"SY Choi","year":"2020","unstructured":"Choi SY, Yang BR, Kang HJ, Park KS, Kim HS. Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases. Korean J Intern Med. 2020;35:593\u2013604. https:\/\/doi.org\/10.3904\/kjim.2018.312.","journal-title":"Korean J Intern Med"},{"key":"1482_CR21","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"key":"1482_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24334","volume":"47","author":"H Soleimani","year":"2024","unstructured":"Soleimani H, Mousavi A, Shojaei S, Tavakoli K, Salabat D, et al. Safety and effectiveness of high-intensity statins versus low\/moderate-intensity statins plus ezetimibe in patients with atherosclerotic cardiovascular disease for reaching LDL-C goals: a systematic review and meta-analysis. Clin Cardiol. 2024;47:e24334. https:\/\/doi.org\/10.1002\/clc.24334.","journal-title":"Clin Cardiol"},{"issue":"9","key":"1482_CR23","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, et al. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d). Clin Res Cardiol. 2023;112(9):1212\u20139. https:\/\/doi.org\/10.1007\/s00392-022-02147-3.","journal-title":"Clin Res Cardiol"},{"key":"1482_CR24","doi-asserted-by":"publisher","first-page":"107424842311895","DOI":"10.1177\/10742484231189597","volume":"28","author":"Y Luo","year":"2023","unstructured":"Luo Y, Peng D. Residual atherosclerotic cardiovascular disease risk: focus on non-high-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther. 2023;28:10742484231189596. https:\/\/doi.org\/10.1177\/10742484231189597.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1482_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117312","volume":"383","author":"V Raja","year":"2023","unstructured":"Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, et al. Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook. Atherosclerosis. 2023;383:117312. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117312.","journal-title":"Atherosclerosis"},{"key":"1482_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-04144-y","volume":"24","author":"P Sydhom","year":"2024","unstructured":"Sydhom P, Al-Quraishi B, El-Shawaf M, Osman MT, Naji N, et al. The clinical effectiveness and safety of low\/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24:660. https:\/\/doi.org\/10.1186\/s12872-024-04144-y.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01482-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:36:36Z","timestamp":1758972996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01482-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01482-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.H. Park is an employee of Hanmi Pharmaceutical Co, Ltd and provided statistical analysis execution under academic supervision. S.A. Bae, J.W. Roh and J.W. Son have no conflicts of interest. The academic authors (S.A. Bae and J.W. Roh) had unrestricted data access, made all scientific decisions and take full responsibility for data integrity and accuracy of the analysis. The decision to publish was made solely by the academic investigators.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets generated and\/or analysed during the current study are not publicly available owing to institutional data sharing policies but are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study was approved by the Ethics Committee of Public Institutional Review Board, South Korea (registration no. P01-202111-21-018, date of approval: 25 November 2021). The study was conducted in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants before enrolment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Data and code are available on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and code availability"}},{"value":"Conceptualisation: J.W.R. and S.A.B. Data curation: M.H.P. Methodology: S.A.B. and J.W.R. Investigation: J.W.R. and J.W.S. Formal analysis: M.H.P. and S.A.B. Writing \u2013 original draft: S.A.B. and J.W.R. Writing \u2013 review and editing: all authors. Funding acquisition: S.A.B. Resources: M.H.P. Supervision: S.A.B. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"author contributions"}}]}}